Compare Cytokinetics Inc (CYTK) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while ProShares UltraPro Short QQQ ETF trades at $32.93 (market cap $2.23B). The key difference: Cytokinetics Inc is far larger — about 3.9× ProShares UltraPro Short QQQ ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| CYTK | SQQQ | |
|---|---|---|
Market Cap | $8.62B | $2.23B |
Volume | 2,594,626 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $89.43 |
52-Week Low | $54.76 | $31.83 |
Typical Hold Time | 19 Days | 12 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.02, up 2.93% on the day. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral momentum. As a 3x leveraged inverse ETF designed to profit from Nasdaq 100 declines, SQQQ's performance is directly tied to technology sector weakness. Recent news highlights its potential role as a hedging tool against QQQ holdings during market downturns.
The outlook for SQQQ depends heavily on technology sector performance, with potential gains during Nasdaq 100 declines but significant decay risk during sustained rallies. Investors face substantial volatility risks due to daily rebalancing and compounding effects. Current market conditions suggest continued uncertainty for tech stocks, potentially supporting SQQQ's short-term appeal as a tactical hedge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
